Skip to main content

. 1978 Nov;38(5):631–633. doi: 10.1038/bjc.1978.260

Comparative effects of cyclophosphamide and isophosphamide on Lewis lung carcinoma.

A Corsi, F Calabresi, C Greco

PMCID: PMC2009779 PMID: 728352

631

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Creaven P. J., Allen L. M., Cohen M. H., Nelson R. L. Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724). Cancer Treat Rep. 1976 Apr;60(4):445–449. [PubMed] [Google Scholar]
DeWys W. D. A quantitative model for the study of the growth and treatment of a tumor and its metastases with correlation between proliferative state and sensitivity to cyclophosphamide. Cancer Res. 1972 Feb;32(2):367–373. [PubMed] [Google Scholar]
Van Dyk J. J., Falkson H. C., Van der Merwe A. M., Falkson G. Unexpected toxicity in patients treated with iphosphamide. Cancer Res. 1972 May;32(5):921–924. [PubMed] [Google Scholar]
Wexler H. Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst. 1966 Apr;36(4):641–645. doi: 10.1093/jnci/36.4.641. [DOI] [PubMed] [Google Scholar]
von Ardenne M., Reitnauer P. G., Rohde K. Vergleich von Ifosfamid mit Cyclophosphamid bei der Therapie des DS-Karzinosarkoms der Ratte. Arch Geschwulstforsch. 1971;38(1):15–26. [PubMed] [Google Scholar]

ACTIONS

RESOURCES